Increases in Methamphetamine Injection Among Treatment Admissions in the U.S

Overview

Journal Addict Behav

Specialties Psychiatry
Social Sciences

Date 2022 Sep 26

PMID 36156454

Authors

Christopher M Jones

Beth Han

Puja Seth

Grant Baldwin

Wilson M Compton

Affiliations

Soon will be listed here.

Abstract

Background: Prior research indicates rising methamphetamine use and harms in the U.S., potentially related to increases in methamphetamine injection. To date, research on trends and correlates of methamphetamine injection is limited.

Methods: Analysis of trends and correlates of methamphetamine injection among treatment admissions among persons aged ≥ 12 whose primary substance of use at admission is methamphetamine. Data are from the Treatment Episode Data Set. Analyses includes descriptive statistics, trend analyses, and multilevel multivariable logistic regression.

Results: Primary methamphetamine treatment admissions increased from 138,379 in 2010 to 201,021 in 2019. Among primary methamphetamine admissions, injection as the usual route of use increased from 24,821 (18.0 % of admissions) in 2010 to 55,951 (28.2 % of admissions) in 2019. Characteristics associated with increased adjusted odds of reporting methamphetamine injection included: males (aOR = 1.13, 95 % CI = 1.10-1.15); admission age 25-34 years (aOR = 1.23, 95 % CI = 1.19-1.28) and 35-44 years (aOR = 1.12, 95 % CI = 1.08-1.17) compared to age 18-24; dependent living (aOR = 1.33, 95 % CI = 1.29-1.37) and homelessness (aOR = 1.58, 95 % CI = 1.54-1.63) compared to independent living; part-time employment (aOR = 1.08, 95 % CI = 1.02-1.14), unemployment (aOR = 1.39, 95 % CI = 1.34-1.44) and not in labor force (aOR = 1.43, 95 % CI = 1.37-1.49) compared to full-time employment; one to ≥ four prior treatment admissions (aORs ranging from 1.19 to 1.94) compared to no prior admissions; also reporting use of cocaine (aOR = 1.10, 95 % CI = 1.05-1.16), heroin (aOR = 3.52, 95 % CI = 3.40-3.66), prescription opioids (aOR = 1.61, 95 % CI = 1.54-1.67), or benzodiazepines (aOR = 1.42, 95 % CI = 1.32-1.52) at treatment admission.

Conclusions: Findings lend further evidence to a resurgence of methamphetamine use that is intertwined with the ongoing opioid crisis in the U.S. Efforts to expand evidence-based prevention, treatment, and response efforts, particularly to populations at highest risk, are urgently needed.

Citing Articles

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Yang K, Kepner W, Cleland C, Palamar J J Affect Disord. 2025; 373:345-352.

PMID: 39746553 PMC: 11794009. DOI: 10.1016/j.jad.2024.12.108.

Decrease in injection and rise in smoking and snorting of heroin and synthetic opioids, 2000-2021.

Karandinos G, Unick J, Ondocsin J, Holm N, Mars S, Montero F Drug Alcohol Depend. 2024; 263:111419.

PMID: 39216201 PMC: 11684856. DOI: 10.1016/j.drugalcdep.2024.111419.

Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021.

Pro G, Cantor J, Buttram M, Brown C, Gu M, Mancino M Med Care. 2024; 62(7):464-472.

PMID: 38761164 PMC: 11834168. DOI: 10.1097/MLR.0000000000002013.

Evidence of telescoping in females across two decades of US treatment admissions for injection drug use: 2000-2020.

Bormann N, Miskle B, Holdefer P, Arndt S, Lynch A, Weber A Drug Alcohol Depend Rep. 2023; 9:100204.

PMID: 38045494 PMC: 10690569. DOI: 10.1016/j.dadr.2023.100204.

The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review.

Russell C, Law J, Imtiaz S, Rehm J, Le Foll B, Ali F Addict Sci Clin Pract. 2023; 18(1):48.

PMID: 37587456 PMC: 10433668. DOI: 10.1186/s13722-023-00402-0.

References

Han B, Cotto J, Etz K, Einstein E, Compton W, Volkow N . Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. JAMA Psychiatry. 2021; 78(5):564-567. PMC: 8100861. DOI: 10.1001/jamapsychiatry.2020.4321. View

Petry N, Alessi S, Olmstead T, Rash C, Zajac K . Contingency management treatment for substance use disorders: How far has it come, and where does it need to go?. Psychol Addict Behav. 2017; 31(8):897-906. PMC: 5714694. DOI: 10.1037/adb0000287. View

Trivedi M, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T . Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021; 384(2):140-153. PMC: 8111570. DOI: 10.1056/NEJMoa2020214. View

Mattson C, Tanz L, Quinn K, Kariisa M, Patel P, Davis N . Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021; 70(6):202-207. PMC: 7877587. DOI: 10.15585/mmwr.mm7006a4. View

Cepeda J, Vickerman P, Bruneau J, Zang G, Borquez A, Farrell M . Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. Drug Alcohol Depend. 2020; 213:108135. PMC: 7829087. DOI: 10.1016/j.drugalcdep.2020.108135. View

Spoth R, Redmond C, Shin C, Greenberg M, Clair S, Feinberg M . Substance-use outcomes at 18 months past baseline: the PROSPER Community-University Partnership Trial. Am J Prev Med. 2007; 32(5):395-402. PMC: 2869212. DOI: 10.1016/j.amepre.2007.01.014. View

Lyss S, Buchacz K, McClung R, Asher A, Oster A . Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs-United States, 2016-2019: Perspectives on Recent Experience and Lessons Learned. J Infect Dis. 2020; 222(Suppl 5):S239-S249. DOI: 10.1093/infdis/jiaa112. View

Li M, Alba G, Mitton J, Bearnot B . Care-engaged individuals with polysubstance use in Northeastern US are undertreated for methamphetamine use disorder: a retrospective cohort study. Addict Sci Clin Pract. 2021; 16(1):57. PMC: 8474730. DOI: 10.1186/s13722-021-00267-1. View

Bach P, Hayashi K, Milloy M, Nosova E, Kerr T, Wood E . Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: A gender-based analysis. Drug Alcohol Rev. 2020; 39(7):932-940. PMC: 7683370. DOI: 10.1111/dar.13126. View

10.

Spoth R, Redmond C, Shin C, Greenberg M, Feinberg M, Trudeau L . PROSPER delivery of universal preventive interventions with young adolescents: long-term effects on emerging adult substance misuse and associated risk behaviors. Psychol Med. 2017; 47(13):2246-2259. PMC: 5963524. DOI: 10.1017/S0033291717000691. View

11.

Al-Tayyib A, Koester S, Langegger S, Raville L . Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern. Subst Use Misuse. 2017; 52(8):1051-1058. PMC: 5642954. DOI: 10.1080/10826084.2016.1271432. View

12.

Glick S, Klein K, Tinsley J, Golden M . Increasing Heroin-Methamphetamine (Goofball) Use and Related Morbidity Among Seattle Area People Who Inject Drugs. Am J Addict. 2020; 30(2):183-191. PMC: 8629025. DOI: 10.1111/ajad.13115. View

13.

Binswanger I, Kral A, Bluthenthal R, Rybold D, Edlin B . High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000; 30(3):579-81. DOI: 10.1086/313703. View

14.

Jones C, Underwood N, Compton W . Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17. Addiction. 2019; 115(2):347-353. PMC: 6982538. DOI: 10.1111/add.14812. View

15.

Paulus M, Stewart J . Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review. JAMA Psychiatry. 2020; 77(9):959-966. PMC: 8098650. DOI: 10.1001/jamapsychiatry.2020.0246. View

16.

Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View

17.

Liu S, Scholl L, Hoots B, Seth P . Nonfatal Drug and Polydrug Overdoses Treated in Emergency Departments - 29 States, 2018-2019. MMWR Morb Mortal Wkly Rep. 2020; 69(34):1149-1155. PMC: 7451974. DOI: 10.15585/mmwr.mm6934a1. View

18.

Broz D, Carnes N, Chapin-Bardales J, Des Jarlais D, Handanagic S, Jones C . Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them. Am J Prev Med. 2021; 61(5 Suppl 1):S118-S129. PMC: 11334402. DOI: 10.1016/j.amepre.2021.05.044. View

19.

ODonnell J, Gladden R, Mattson C, Hunter C, Davis N . Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants - 24 States and the District of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020; 69(35):1189-1197. PMC: 7470457. DOI: 10.15585/mmwr.mm6935a1. View

20.

Higgins S, Kurti A, Davis D . Voucher-Based Contingency Management is Efficacious but Underutilized in Treating Addictions. Perspect Behav Sci. 2020; 42(3):501-524. PMC: 6768932. DOI: 10.1007/s40614-019-00216-z. View